Table 4. Detection of IFN-γ–secreting... | American Society of Hematology

Table 4.

Detection of IFN-γ–secreting cells by ELISPOT analysis in the peripheral blood of cancer patients and healthy donors

	Diagnosis	CYP190*	CYP239	TAX†	EBV	OKT-3
*Cancer patients*	MM	15	5	10	*116*	*1335*
	MM	0	5	5	152	1289
	FL	0	ND	2	60	*756*
	CaP	16	ND	5	37	654
	MM	ND	0	0	46	*922*
	MM	ND	5	0	10	670
	MM	ND	0	2	18	*1489*
	MM	0	ND	0	216	1205
*Healthy donors*	HD	0	0	0	*168*	*792*
	HD	0	0	7	109	252
	HD	0	0	0	*120*	*1894*
	HD	0	0	0	335	756
	HD	7	0	7	65	*562*

	Diagnosis	CYP190*	CYP239	TAX†	EBV	OKT-3
*Cancer patients*	MM	15	5	10	*116*	*1335*
	MM	0	5	5	152	1289
	FL	0	ND	2	60	*756*
	CaP	16	ND	5	37	654
	MM	ND	0	0	46	*922*
	MM	ND	5	0	10	670
	MM	ND	0	2	18	*1489*
	MM	0	ND	0	216	1205
*Healthy donors*	HD	0	0	0	*168*	*792*
	HD	0	0	7	109	252
	HD	0	0	0	*120*	*1894*
	HD	0	0	0	335	756
	HD	7	0	7	65	*562*

MM indicates multiple myeloma; FL, follicular lymphoma; ND, not determined; CaP, cancer of the prostate; and HD, healthy donor.

All values given in spot-forming cells/100 000 CD8⁺ T cells.

HTLV-TAX, negative control; EBV-BMLF-1, positive control.